期刊
FRONTIERS IN ONCOLOGY
卷 10, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2020.01389
关键词
MDMX; MDM2; p53; oncogene; tumor suppressor; inhibitors
类别
资金
- National Natural Science Foundation of China [81903842, 81573953]
- Program of Zhejiang Provincial TCM Sci-tech Plan [2020ZZ005, 2016ZZ012]
- Zhejiang Chinese Medical University [111100E014]
- Medical Science and Technology Project of Zhejiang Province [WKJ-ZJ-1728]
- Traditional Chinese Medical Science and Technology Major Project of Zhejiang Province [2018ZY006]
- Science and Technology Projects of Zhejiang Province [2019C03049]
The oncogene MDMX, also known as MDM4 is a critical negative regulator of the tumor suppressor p53 and has been implicated in the initiation and progression of human cancers. Increasing evidence indicates that MDMX is often amplified and highly expressed in human cancers, promotes cancer cell growth, and inhibits apoptosis by dampening p53-mediated transcription of its target genes. Inhibiting MDMX-p53 interaction has been found to be effective for restoring the tumor suppressor activity of p53. Therefore, MDMX is becoming one of the most promising molecular targets for developing anticancer therapeutics. In the present review, we mainly focus on the current MDMX-targeting strategies and known MDMX inhibitors, as well as their mechanisms of action andin vitroandin vivoanticancer activities. We also propose other potential targeting strategies for developing more specific and effective MDMX inhibitors for cancer therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据